SGN-B6A

CAT: 0804-HY-164957-01Size: 1 mgDry Ice: YesHazardous: No
CAT#:0804-HY-164957-01Size:1 mg
Selected
PRICE
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
SGN-B6A is an ADC, which targets integrin beta-6 (ITGB6) through human IgG1 monoclonal antibody Sigvotatug (HY-P990764), and exhibits cytotoxicity against multiple integrin beta-6-positive cancer cell through mitotic inhibitor MMAE (HY-15162) [1].
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs) ; Integrin
Type
ADC Related
Related Pathways
Antibody-drug Conjugate/ADC Related; Cytoskeleton
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/sgn-b6a.html
Purity
99.68
Smiles
[SGN-B6A]
Molecular Weight
150000 (average)
References & Citations
[1]Lyon RP, et al., SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications. Mol Cancer Ther. 2023 Dec 1;22 (12) :1444-1453.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Scientific Category
ADC Related
Clinical Information
No Development Reported

Related Products

CatalogName
HY-107366-01SGN-2FF
HY-P991512SGN-30

Alternative Products

CatalogName
MF-0101209-01SGN-B6A
DHD29901Research Grade Anti-Human ITGB6 (SGN-B6A)
A136483Anti-ITGB6 (SGN-B6A) Biosimilar (Monoclonal, IgG1-kappa)
OR1077715SgN
BUP04680-01SGN-2FF
296962-01DNS-SGN
MF-0100867-01SGN-30
464893SGN-46810
A19196-100SGN-2FF 100mg
A19196-5SGN-2FF 5mg

Popular Products